Active substance

Results for the substance pirtobrutinib

2 results

About this active substance

Pirtobrutinib is a selective Bruton tyrosine kinase (BTK) inhibitor used in the treatment of certain types of lymphomas and leukemias, including mantle cell lymphoma and chronic lymphocytic leukemia. It works by blocking BTK activity, inhibiting tumor cell growth and survival.

The medication is taken orally, as directed by a doctor, usually once daily. It is important for patients to follow the treatment regimen and undergo regular tests to monitor the therapy's effects.

Patients should be aware of potential side effects, such as fatigue, nausea, or infections. It is important to inform the doctor of any unusual symptoms.

Common side effects include fatigue, nausea, and infections. In rare cases, severe reactions such as bleeding, cardiac arrhythmias, or allergic reactions may occur. Patients should be informed of these risks before use.